186 related articles for article (PubMed ID: 32042081)
1. Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group.
Hoechstetter MA; Busch R; Eichhorst B; Bühler A; Winkler D; Bahlo J; Robrecht S; Eckart MJ; Vehling-Kaiser U; Jacobs G; Jäger U; Hurtz HJ; Hopfinger G; Hartmann F; Fuss H; Abenhardt W; Blau I; Freier W; Müller L; Goebeler M; Wendtner C; Fischer K; Herling CD; Starck M; Bentz M; Emmerich B; Döhner H; Stilgenbauer S; Hallek M
Leukemia; 2020 Apr; 34(4):1038-1051. PubMed ID: 32042081
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of four prognostic scoring system in patients with early asymptomatic chronic lymphocytic leukemia patients].
Sha YQ; Shen H; Wu W; Xia Y; Miao Y; Cao L; Wang L; Fan L; Xu W; Li JY; Zhu HY
Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):834-839. PubMed ID: 34788923
[No Abstract] [Full Text] [Related]
3. The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients.
Molica S; Shanafelt TD; Giannarelli D; Gentile M; Mirabelli R; Cutrona G; Levato L; Di Renzo N; Di Raimondo F; Musolino C; Angrilli F; Famà A; Recchia AG; Chaffee KG; Neri A; Kay NE; Ferrarini M; Morabito F
Am J Hematol; 2016 Nov; 91(11):1090-1095. PubMed ID: 27465919
[TBL] [Abstract][Full Text] [Related]
4. Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol.
Morabito F; Tripepi G; Vigna E; Bossio S; D'Arrigo G; Martino EA; Storino F; Recchia AG; Fronza G; Di Raimondo F; Colombo M; Fais F; Neri A; Cutrona G; Ferrarini M; Gentile M
Eur J Haematol; 2021 Jun; 106(6):831-835. PubMed ID: 33662164
[TBL] [Abstract][Full Text] [Related]
5. Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia.
Morabito F; Tripepi G; Moia R; Recchia AG; Boggione P; Mauro FR; Bossio S; D'Arrigo G; Martino EA; Vigna E; Storino F; Fronza G; Di Raimondo F; Rossi D; Condoluci A; Colombo M; Fais F; Fabris S; Foa R; Cutrona G; Gentile M; Montserrat E; Gaidano G; Ferrarini M; Neri A
Front Oncol; 2021; 11():684621. PubMed ID: 34408978
[TBL] [Abstract][Full Text] [Related]
6. Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia.
Li H; Yi SH; Xiong WJ; Liu HM; Lyu R; Wang TY; Liu W; Zhong SZ; Yu Z; Zou DH; Xu Y; An G; Li ZJ; Qiu LG
Chin Med J (Engl); 2017 Jan; 130(2):135-142. PubMed ID: 28091403
[TBL] [Abstract][Full Text] [Related]
7. Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients.
Baumann T; Moia R; Gaidano G; Delgado J; Condoluci A; Villamor N; Payedimarri AB; Costa D; Patriarca A; Jiménez-Vicente C; Rossi D; Montserrat E
Leukemia; 2021 Aug; 35(8):2325-2331. PubMed ID: 33542480
[TBL] [Abstract][Full Text] [Related]
8. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.
Kreuzberger N; Damen JA; Trivella M; Estcourt LJ; Aldin A; Umlauff L; Vazquez-Montes MD; Wolff R; Moons KG; Monsef I; Foroutan F; Kreuzer KA; Skoetz N
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD012022. PubMed ID: 32735048
[TBL] [Abstract][Full Text] [Related]
9. Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.
Delgado J; Doubek M; Baumann T; Kotaskova J; Molica S; Mozas P; Rivas-Delgado A; Morabito F; Pospisilova S; Montserrat E
Am J Hematol; 2017 Apr; 92(4):375-380. PubMed ID: 28120419
[TBL] [Abstract][Full Text] [Related]
10. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia.
Condoluci A; Terzi di Bergamo L; Langerbeins P; Hoechstetter MA; Herling CD; De Paoli L; Delgado J; Rabe KG; Gentile M; Doubek M; Mauro FR; Chiodin G; Mattsson M; Bahlo J; Cutrona G; Kotaskova J; Deambrogi C; Smedby KE; Spina V; Bruscaggin A; Wu W; Moia R; Bianchi E; Gerber B; Zucca E; Gillessen S; Ghielmini M; Cavalli F; Stussi G; Hess MA; Baumann TS; Neri A; Ferrarini M; Rosenquist R; Forconi F; Foà R; Pospisilova S; Morabito F; Stilgenbauer S; Döhner H; Parikh SA; Wierda WG; Montserrat E; Gaidano G; Hallek M; Rossi D
Blood; 2020 May; 135(21):1859-1869. PubMed ID: 32267500
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG).
Jaramillo S; Agathangelidis A; Schneider C; Bahlo J; Robrecht S; Tausch E; Bloehdorn J; Hoechstetter M; Fischer K; Eichhorst B; Goede V; Hallek M; Döhner H; Rosenquist R; Ghia P; Stamatopoulos K; Stilgenbauer S
Haematologica; 2020 Nov; 105(11):2598-2607. PubMed ID: 33131249
[TBL] [Abstract][Full Text] [Related]
12. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data.
International CLL-IPI working group
Lancet Oncol; 2016 Jun; 17(6):779-790. PubMed ID: 27185642
[TBL] [Abstract][Full Text] [Related]
13. Comparative assessment of prognostic models in chronic lymphocytic leukemia: evaluation in Indian cohort.
Rani L; Gogia A; Singh V; Kumar L; Sharma A; Kaur G; Gupta R
Ann Hematol; 2019 Feb; 98(2):437-443. PubMed ID: 30338367
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
Soumerai JD; Ni A; Xing G; Huang J; Furman RR; Jones J; Sharman JP; Hallek M; Adewoye AH; Dubowy R; Dreiling L; Zelenetz AD
Leuk Lymphoma; 2019 Jun; 60(6):1438-1446. PubMed ID: 30407886
[TBL] [Abstract][Full Text] [Related]
15. Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL study.
Gentile M; Cutrona G; Fabris S; Pesce EA; Baldini L; Di Raimondo F; Musolino C; Di Tonno P; Di Renzo N; Molica S; Brugiatelli M; Ilariucci F; Zupo S; Matis S; Maura F; Vigna E; Angrilli F; Recchia AG; Quarta G; Iannitto E; Fragasso A; Musto P; Spriano M; Vincelli I; Vallisa D; Cortelezzi A; Mauro FR; Foà R; Federico M; Neri A; Ferrarini M; Morabito F
Am J Hematol; 2013 Jul; 88(7):539-44. PubMed ID: 23553682
[TBL] [Abstract][Full Text] [Related]
16. Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study.
Gentile M; Cutrona G; Mosca L; Matis S; Fabris S; Lionetti M; Ilariucci F; Zupo S; Musolino C; Levato L; Molica S; Di Raimondo F; Vincelli I; Di Rienzo N; Pesce EA; Angrilli F; Federico M; Neri A; Ferrarini M; Morabito F
Am J Hematol; 2014 Jul; 89(7):743-50. PubMed ID: 24711230
[TBL] [Abstract][Full Text] [Related]
17. Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients.
Hu B; Patel KP; Chen HC; Wang X; Luthra R; Routbort MJ; Kanagal-Shamanna R; Medeiros LJ; Yin CC; Zuo Z; Ok CY; Loghavi S; Tang G; Tambaro FP; Thompson P; Burger J; Jain N; Ferrajoli A; Bose P; Estrov Z; Keating M; Wierda WG
Br J Haematol; 2019 Nov; 187(3):307-318. PubMed ID: 31243771
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry.
Mato A; Nabhan C; Kay NE; Lamanna N; Kipps TJ; Grinblatt DL; Flowers CR; Farber CM; Davids MS; Kiselev P; Swern AS; Bhushan S; Sullivan K; Flick ED; Sharman JP
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):114-124.e2. PubMed ID: 29352719
[TBL] [Abstract][Full Text] [Related]
19. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
[TBL] [Abstract][Full Text] [Related]
20. Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?
Brieghel C; Galle V; Agius R; da Cunha-Bang C; Andersen MA; Vlummens P; Mattsson M; Rosenquist R; Smedby KE; Herling CD; Bahlo J; Hallek M; Lundgren JD; Offner F; Niemann CU
Eur J Haematol; 2022 May; 108(5):369-378. PubMed ID: 35030282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
